A One-year, Phase III, Open-label, Non-comparative Trial of the Effect of Ziprasidone HCl on Metabolic Syndrome Risk Factors in Patients With Bipolar I Disorder.

Trial Profile

A One-year, Phase III, Open-label, Non-comparative Trial of the Effect of Ziprasidone HCl on Metabolic Syndrome Risk Factors in Patients With Bipolar I Disorder.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 06 Jul 2012

At a glance

  • Drugs Ziprasidone (Primary)
  • Indications Bipolar I disorders
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Apr 2011 Planned end date changed from 1 Jan 2011 to 1 Feb 2011 as reported by ClinicalTrials.gov.
    • 03 Mar 2011 Planned End Date changed from 1 Feb 2011 to 1 Jan 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top